Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

NCT07718737 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: AMT-116
DRUG: Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)

Sponsor

Multitude Therapeutics Inc.